Douglas J. Zeckner - Concepedia

Concepedia

Author

Douglas J. Zeckner

Eli Lilly (United States)

Also Known As

DOUGLAS J. ZECKNER, Douglas J Zeckner, Douglas J. Zeckner, Douglas Zeckner

31

Publications

1.8K

Citations

10

H-Index

28

Concepts

All Affiliations

Eli Lilly (United States)

DJ

About

Douglas J. Zeckner is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and antifungal agents.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	1.6K
2	Natural Sciences	2	2	122
3	Biochemistry	2	2	122
4	Engineering	1	1	10
5	Biomolecular Engineering	1	1	19

Douglas J. Zeckner

×

13

Publications

1.8K

Citations

10

H-Index

	Year	Citations
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer John D. Carpten, Andrew L. Faber, Candice L. Horn, Nature Somatic VariantMedicinePleckstrin Homology DomainCancer GeneticsSystems Biology	2007	1.3K
Semisynthetic Chemical Modification of the Antifungal Lipopeptide Echinocandin B (ECB): Structure-Activity Studies of the Lipophilic and Geometric Parameters of Polyarylated Acyl Analogs of ECB Manuel Debono, William W. Turner, Lisa LaGrandeur, Journal of Medicinal Chemistry Semisynthetic Chemical ModificationGeometric ParametersChemical BiologyLinoleic AcidPharmaceutical Chemistry	1995	112
In vitro and in vivo anti-Candida activity and toxicology of LY121019. Robert S. Gordee, Douglas J. Zeckner, L. F. Ellis, The Journal of Antibiotics	1984	109
A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models Tinggui Yin, Marı́a José Lallena, Emiko L. Kreklau, Molecular Cancer Therapeutics Tumor BiologyMedicineMalignant Blood DisorderImmunologyCell Death	2014	101
Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth Michèle C. Smith, Mary M. Mader, James A. Cook, Molecular Cancer Therapeutics	2016	74
Anti‐<i>Candida</i> Activity and Toxicology of LY121019, a Novel Semisynthetic Polypeptide Antifungal Antibiotica Robert S. Gordee, Douglas J. Zeckner, Leonard C. Howard, Annals of the New York Academy of Sciences Antimicrobial Drug DiscoveryAntifungal AgentAntifungal AgentsMedicineAntimicrobial Chemotherapy	1988	58
Correlation of cilofungin in vivo efficacy with its activity against<i>Aspergillus fumigatus</i>(1,3)-Î²-d-glucan synthase Danielle Beaulieu, Julia Tang, Douglas J. Zeckner, FEMS Microbiology Letters	1993	33
Syntheses and antifungal activities of novel 3-amido bearing pseudomycin analogues Yan‐Zhi Zhang, Xicheng Sun, Douglas J. Zeckner, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryAntifungal AgentAntimicrobial CompoundPharmacologyPharmaceutical Chemistry	2001	19
N -Acyloxymethyl carbamate linked prodrugs of pseudomycins are novel antifungal agents Xicheng Sun, Douglas J. Zeckner, William L. Current, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryAntifungal AgentAntifungal AgentsMedicineN -Acyloxymethyl Carbamate	2001	17
8-amido-bearing pseudomycin B (PSB) analogue: novel antifungal agents Yan‐Zhi Zhang, Xicheng Sun, Douglas J. Zeckner, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryAntifungal AgentAntifungal AgentsMedicine8-Amido-bearing Pseudomycin B	2001	13

Page 1